GSDME (Gasdermin E, also historically known as DFNA5) is a gene located on chromosome 7p15.3 that encodes the gasdermin E protein — a member of the gasdermin family of pore-forming proteins. Originally identified through its role in autosomal dominant nonsensory hearing loss (DFNA5), GSDME has emerged as a critical player in programmed cell death, particularly through its involvement in pyroptosis, with significant implications for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and stroke[1][2].
The gasdermin family shares a conserved architecture: an N-terminal effector domain that can form pores in lipid membranes, and a C-terminal inhibitory domain that suppresses activity in the full-length protein. Proteolytic cleavage releases the N-terminal fragment, which then oligomerizes to form pores in the plasma membrane, executing lytic cell death distinct from apoptosis[3].
GSDME is unique among gasdermins because it can be activated by caspase-3, the canonical executioner of apoptosis, creating a bridge between apoptosis and pyroptosis that has profound implications for neuronal survival under stress conditions[4].
GSDME spans approximately 32 kb and consists of 12 exons. The gene produces multiple transcript variants through alternative splicing. The canonical isoform encodes a 496-amino-acid protein with a molecular weight of approximately 55 kDa. The protein contains two major functional domains:
The DFNA5 locus was the first gene mapped for autosomal dominant nonsensory hearing loss. A pathogenic intronic G-to-A transition (c. 2325+5G>A) causes aberrant splicing, producing a truncated protein that exerts dominant-negative effects on cochlear hair cells, leading to progressive high-frequency hearing loss[6]. More than 40 families worldwide carry this mutation. The hearing loss phenotype demonstrates that GSDME is critical for hair cell survival and that its dysregulation leads to permanent sensory deficits — a mechanistic parallel to neuronal vulnerability in neurodegeneration.
Pyroptosis is a lytic, pro-inflammatory form of programmed cell death driven by gasdermin family proteins[3:1]. Unlike apoptosis, which maintains membrane integrity until engulfment by phagocytes, pyroptosis culminates in plasma membrane rupture and release of intracellular contents including IL-1beta, IL-18, and alarmins (e.g., HMGB1, ATP). This makes pyroptosis a highly immunogenic form of cell death.
Mechanism of GSDME activation:
GSDMD is the canonical pyroptosis executioner, activated by inflammatory caspases (caspase-1, -4, -5, -11) in response to pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs)[9]. GSDME provides an alternative pyroptotic pathway triggered by apoptotic stimuli. In cells that express high levels of GSDME, apoptotic stimuli can be "re-wired" toward pyroptosis through caspase-3-mediated GSDME cleavage. This creates a functional switch:
This switch has therapeutic implications: in neurons where GSDME is relatively highly expressed, preventing caspase-3 activation may be crucial for blocking pyroptotic neuronal death[2:1].
GSDME acts as a tumor suppressor. Loss-of-function mutations are found in gastric, breast, colorectal, and other cancers. Re-expression of GSDME in GSDME-deficient tumors induces pyroptotic cell death, limiting tumor growth. This tumor-suppressive function underscores the protein's capacity for regulated, potent cell death when activated.
Autophagy provides a counterbalance to pyroptosis through at least two mechanisms: (1) selective autophagic degradation of GSDME-NT oligomers, limiting pore formation; and (2) autophagic degradation of upstream activators (e.g., inflammasome components)[10]. In neurodegeneration, autophagy impairment — a well-documented feature of Alzheimer's disease and Parkinson's disease — would remove this protective brake, making neurons more vulnerable to pyroptotic death.
GSDME is expressed across multiple brain regions, with particular enrichment in:
Single-cell RNA-seq datasets (Allen Brain Atlas, Human Protein Atlas) confirm GSDME expression in neurons, astrocytes, and microglia, with elevated baseline expression in neurons relative to glia[11].
GSDME-mediated pyroptosis plays a significant role in Alzheimer's disease through multiple pathways[4:1][12]:
Key evidence:
In Parkinson's disease, GSDME contributes to dopaminergic neuron death through several mechanisms[13]:
Key evidence:
Motor neuron death in ALS involves both apoptosis and pyroptosis. GSDME is activated by mutant SOD1, TDP-43, and FUS through caspase-3-dependent pathways:
Cerebral ischemia-reperfusion strongly activates GSDME-mediated pyroptosis in neurons:
GSDME activation has been reported in Huntington's disease models, where mutant huntingtin triggers caspase-3 activation and GSDME cleavage in striatal neurons, contributing to medium spiny neuron loss.
DEVD-CHO and other caspase-3 inhibitors prevent GSDME cleavage in neurons. However, systemic caspase-3 inhibition carries risks (impaired wound healing, immune dysfunction) and may simply redirect cell death from pyroptosis to necrosis[12:1].
No selective GSDME-NT inhibitors exist currently, but peptides mimicking the C-terminal inhibitory domain (residues 276-496) can be delivered to neurons and are being explored as therapeutic agents[2:3].
Since inflammasome activation is an upstream trigger of GSDME pathway in some contexts, MCC950 (NLRP3 inhibitor) has shown benefit in reducing pyroptotic neuronal death.
Allele-specific silencing for the DFNA5 hearing loss variant using antisense oligonucleotides. Similar approaches could be designed to reduce GSDME expression in neurons if needed.
Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018. ↩︎
Tan MS, Yang J, Xu Z, et al. Gasdermin E in neurological diseases: a guardian or a killer?. Prog Neurobiol. 2023. ↩︎ ↩︎ ↩︎ ↩︎
Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2017. ↩︎ ↩︎
Huang R, Meng T, Zhu Z, et al. Inflammasome-dependent neuronal pyroptosis in Alzheimer's disease. J Neuroinflammation. 2023. ↩︎ ↩︎
Xia X, Wang X, Zheng Y, et al. What role does GSDME play in chemotherapy-induced tissue injury?. Trends Cell Biol. 2021. ↩︎
Broz P, Pelegrin P, Shao F. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nat Rev Immunol. 2020. ↩︎
Liu X, Zhang Z, Ruan J, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016. ↩︎
Feng Y, Li Z, Liu J, et al. GSDME-mediated pyroptosis in neurodegeneration: new Frontiers. Mol Neurodegener. 2022. ↩︎
Wang Y, Gao W, Shi X, et al. Pyroptosis and Alzheimer's disease: gasdermin D in neurodegeneration. J Neuroinflammation. 2021. ↩︎
Liu Y, Cao M, Cai Y, et al. Crosstalk between pyroptosis and autophagy in neurodegenerative diseases. Cell Mol Neurobiol. 2021. ↩︎
Yi Q, Tan J, Peng W, et al. The emerging role of GSDME in neurological disorders. Mol Brain. 2024. ↩︎
Tao P, Yu Q, Chen X, et al. Targeting pyroptosis for Alzheimer's disease therapy. Ageing Res Rev. 2024. ↩︎ ↩︎
Chen L, Guan R, Zhou Y, et al. Pyroptosis in Parkinson's disease: mechanisms and therapeutic strategies. Front Mol Neurosci. 2024. ↩︎